News

Newly developed bioink enhances the ability of implanted cells to grow and regenerate new tissue.

News emerged today (September 9) that a Phase III clinical trial of the COVID-19 vaccine ChAdOX1 – a recombinant adenovirus vaccine developed by the University of Oxford and AstraZeneca – has been paused.

A targeted therapy called capmatinib provides significant benefits to patients who have advanced lung cancer with specific gene mutations, according to the results of a Phase 2 trial.

A Phase 3 global clinical trial has shown that an experimental drug called vosoritide is able to boost bone growth in children born with achondroplasia, the most common type of dwarfism.

Researchers have identified the cause of dilated cardiomyopathy, a leading cause of heart failure, and have discovered a potential treatment for it – a drug already used to treat acne.

A team has identified a “polygenic risk score” that shows when a drug poses a risk of causing drug-induced liver injury.

An innovative genetic study of blood protein levels, led by researchers in the MRC Integrative Epidemiology Unit (MRC-IEU) at the University of Bristol, has demonstrated how genetic data can be used to support drug target prioritisation by identifying the causal effects of proteins on diseases.

A meta-analysis of non-human primate (NHP) studies showed that adeno-associated virus (AAV) gene therapy often caused dorsal root ganglion (DRG) pathology. There were no clinical effects.

Nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution — called the Fair Priority Model — which aims to reduce premature deaths and other irreversible health consequences from COVID-19.

In a new study, researchers demonstrated that a candidate COVID-19 vaccine elicited robust immune response in Syrian golden hamsters and prevented severe clinical disease — including weight loss, pneumonia and death.